Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035692 | 1.00 | PIK3C3 (0.41) | PIK3C3HSD11B1NAMPTSSTR4TAS1R3 | |
| SCHEMBL6411893 | 0.84 | NAMPT (0.46) | NAMPT | |
| SCHEMBL6412974 | 0.83 | NPC1 (0.38) | TAS1R3TAS1R1TAS1R2CHRNA7 | |
| SCHEMBL6415309 | 0.83 | HDAC1 (0.42) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7033391 | 0.83 | NPC1 (0.36) | CHRNA7 | |
| SCHEMBL6410363 | 0.83 | NPC1 (0.36) | CHRNA7 | |
| SCHEMBL6417961 | 0.82 | CHRNA7 (0.37) | PIK3C3SSTR4HTR3ACHRNA7 | |
| SCHEMBL6414838 | 0.81 | CHRNA7 (0.43) | HTR3ACHRNA7 | |
| SCHEMBL6417962 | 0.80 | SLC6A2 (0.35) | CHRNA7 | |
| SCHEMBL6411631 | 0.80 | KDM1A (0.37) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | claimed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | PIK3C3 2287/4885HSD11B1 272/4885NAMPT 353/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | PIK3C3 3817/4885HSD11B1 932/4885NAMPT 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.